European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL More>>

SGS QUAY PHARMA RECEIVES QUEEN’S AWARD FOR INDUSTRY

Leading pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has received its Queen’s Award for Enterprise. The award was presented by the Lord Lieutenant of Clwyd, Henry Fetherstonhaugh, OBE, in a special ceremony at the company’s global headquarters in Deeside Industrial Park, Flintshire. More>>

Signant Partners with Loftware for Adaptive Investigational Product Labeling

Collaboration reinforces Signant's end-to-end clinical supplies management solutions and supports the complex manufacturing and distribution models inherent in modern clinical research More>>

European Pharma Needs to Keep Manufacturing On The Continent And Become More Digitised To Stay Competitive, Say Speakers At New Event

The newly announced agenda for Connect in Pharma focuses on innovation as the foundation of a strong pharmaceutical industry in Europe More>>

Pioneering a New Era of Cell Therapy Manufacturing

Memphis facility becomes first North American CDMO to receive EMA approval for commercial allogeneic cell therapy production

Aug 09 2022: Following its successful inspection, our Memphis cell therapy manufacturing facility is paving the way in the cell and gene therapy industry as the first contract development and manufacturing organization (CDMO) in North America to be awarded a commercial GMP license to produce allogeneic cell therapy drug products from the European Medicines Agency (EMA). More>>

Sartorius to Acquire Albumedix, Strengthening its Portfolio of Innovative Advanced Therapy Solutions

Göttingen, August 8, 2022: The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. The business, founded in 1984, has more than 100 employees and is expected to generate revenue of approximately £33 million in 2022 with a significant double-digit EBITDA margin. The agreed purchase price amounts to approximately £415 million. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022. More>>

Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform

09 Aug 2022, Darmstadt, Germany: Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development. This new platform enables biopharmaceutical companies to increase the speed to clinical manufacturing while reducing process development time and costs. More>>

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Cerevance to concurrently out-license one discovery-stage program

Boston, MA and Cambridge, UK – AUGUST 9, 2022: Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration. More>>

Jackson ImmunoResearch Announces New Range of Antibodies for Serology and Diagnostics Market

West Grove, PA – 02 August 2022: Jackson ImmunoResearch, a manufacturer of secondary antibodies and immunoreagents for the life science market, announces a new addition to its range of products for scientists developing immunoassays for the serology and diagnostics markets. JIR Mouse Monoclonal Anti-Human IgE antibodies are the latest addition to our suite of products suitable for diagnostics research and development. More>>

BioIVT Acquires Cypex, a Leading Manufacturer of Drug-Metabolizing Enzymes

Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development

Westbury, NY – August 8, 2022 – BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism. More>>